Volume 16, Number 8—August 2010
CME ACTIVITY - Synopsis
Clostridium difficile Bacteremia, Taiwan1
Table 3
In vitro antimicrobial drug susceptibilities of 10 bacteremic Clostridium difficile isolates, Taiwan, 1989–2009*
Antimicrobial agent | MIC, μg/mL |
Resistance breakpoint, μg/mL | No. (%) resistant isolates | ||
---|---|---|---|---|---|
Range | MIC50 | MIC90 | |||
Vancomycin† | 0.5–1 | 0.5 | 1 | >2 | 0 |
Metronidazole | 0.25–8 | 1 | 4 | >32 | 0 |
Clindamycin | 0.03–>256 | 4 | >256 | >8 | 3 (30) |
Penicillin | 0.25–8 | 4 | 4 | >2 | 9 (90) |
Ampicillin/sulbactam | 0.5–8 | 2 | 4 | >32/16 | 0 |
Cefmetazole | 0.25–32 | 16 | 32 | >64 | 0 |
Meropenem | 0.12–2 | 1 | 2 | >16 | 0 |
Imipenem | 0.12–16 | 8 | 16 | >16 | 4 (40) |
Ertapenem | 0.06–16 | 8 | 8 | >16 | 0 |
Doripenem | 0.12–8 | 4 | 4 | NA | NA |
Daptomycin | 0.12–2 | 0.5 | 2 | NA | NA |
Tigecycline | 0.03–0.12 | 0.03 | 0.06 | NA | NA |
Fusidic acid | 1–8 | 1 | 2 | NA | NA |
*MIC50, 50% MIC; MIC90, 90% MIC, NA, not available.
†Vancomycin MIC breakpoint was recommended by the European Committee on Antimicrobial Susceptibility Testing (www.eucast.org); otherwise by the Clinical and Laboratory Standards Institute (22).
References
- McCabe WR, Jackson GG. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med. 1962;110:847–55.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55. DOIPubMed
- Baron EJ, Weissfeld AS, Fuselier PA, Brenner DJ. Classification and identification of bacteria. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 6th ed. Washington: American Society for Microbiology Press; 1995. p. 249–64.
- Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 7th ed. M11–A7. Wayne (PA): The Institute; 2007.
- Cid A, Juncal AR, Aguilera A, Regueiro BJ, Gonzalez V. Clostridium difficile bacteremia in an immunocompetent child. J Clin Microbiol. 1998;36:1167–8.PubMed
- Genta VM, Gilligan PH, McCarthy LR. Clostridium difficile peritonitis in a neonate. A case report. Arch Pathol Lab Med. 1984;108:82–3.PubMed
- Studemeister AE, Beilke MA, Kirmani N. Splenic abscess due to Clostridium difficile and Pseudomonas paucimobilis. Am J Gastroenterol. 1987;82:389–90.PubMed
- Smith LD, King EO. Occurrence of Clostridium difficile in infections of man. J Bacteriol. 1962;84:65–7.PubMed
- Chen YM, Lee HC, Chang CM, Chuang YC, Ko WC. Clostridium bacteremia: emphasis on the poor prognosis in cirrhotic patients. J Microbiol Immunol Infect. 2001;34:113–8.PubMed
- Bartlett JG. Narrative review: the new epidemic of Clostridium difficile–associated enteric disease. Ann Intern Med. 2006;145:758–64.PubMed
Page created: March 30, 2011
Page updated: March 30, 2011
Page reviewed: March 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.